Literature DB >> 22847801

The role of sequential chemoradiation for local advanced oropharyngeal carcinoma.

Liam Masterson1, Faiz Tanweer.   

Abstract

BACKGROUND: This study aims to assess survival, prognostic indicators, and pattern of failure for advanced oropharyngeal cancer treated by induction chemotherapy followed by concomitant chemoradiation (sequential CRT).
METHODS: A retrospective review of 80 consecutive patients who underwent chemoradiation [doublet cisplatin and 5-fluorouracil (PF)] for local advanced oropharyngeal carcinoma at a tertiary center from March 2003 to July 2008 is reported. Seven studies utilizing a similar protocol were reviewed, and all outcomes are collated. RESULT: At a median follow-up of 32 months, the 3-year overall survival was 75%. Tumor size (p < 0.001), age at presentation (p < 0.002), and failure to complete the full course of induction chemotherapy (p < 0.01) were all found to be significant factors affecting survival.
CONCLUSION: Induction chemotherapy followed by concomitant chemoradiation utilizing doublet PF is an effective treatment for local advanced oropharyngeal carcinoma. At present, the addition of a taxane to the PF regimen cannot be assumed to provide benefit until further evidence emerges from a representative controlled trial.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22847801     DOI: 10.1007/s10147-012-0448-y

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  29 in total

1.  Evidence-based management of oropharyngeal cancer.

Authors:  A K Robson; V Paleri
Journal:  Clin Otolaryngol       Date:  2010-08       Impact factor: 2.597

Review 2.  TPF sequential therapy: when and for whom?

Authors:  Volker Budach
Journal:  Oncologist       Date:  2010

Review 3.  The chemoradiation paradigm in head and neck cancer.

Authors:  Tanguy Y Seiwert; Joseph K Salama; Everett E Vokes
Journal:  Nat Clin Pract Oncol       Date:  2007-03

4.  Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.

Authors:  Volker Budach; Martin Stuschke; Wilfried Budach; Michael Baumann; Dirk Geismar; Gerhard Grabenbauer; Ingrid Lammert; Klaus Jahnke; Georg Stueben; Thomas Herrmann; Michael Bamberg; Peter Wust; Wolfgang Hinkelbein; Klaus-Dieter Wernecke
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

Review 5.  Global epidemiology of oral and oropharyngeal cancer.

Authors:  Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2008-09-18       Impact factor: 5.337

Review 6.  Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity.

Authors:  Maura L Gillison
Journal:  Semin Oncol       Date:  2004-12       Impact factor: 4.929

Review 7.  Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region.

Authors:  Hisham Mehanna; Tom Beech; Tom Nicholson; Iman El-Hariry; Christopher McConkey; Vinidh Paleri; Sally Roberts
Journal:  Head Neck       Date:  2012-01-20       Impact factor: 3.147

8.  Swallowing function after chemoradiation for advanced stage oropharyngeal cancer.

Authors:  Samuel G Shiley; Christopher A Hargunani; Judith M Skoner; John M Holland; Mark K Wax
Journal:  Otolaryngol Head Neck Surg       Date:  2006-03       Impact factor: 3.497

9.  Concurrent chemoradiation for locally advanced oropharyngeal cancer.

Authors:  Nam P Nguyen; Paul Vos; Herbert J Smith; Phuc D Nguyen; Alan Alfieri; Ulf Karlsson; Suresh Dutta; Claire Lemanski; Ly M Nguyen; Sabah Sallah
Journal:  Am J Otolaryngol       Date:  2007 Jan-Feb       Impact factor: 1.808

10.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

View more
  1 in total

1.  Outcome and prognostic factors in T4a oropharyngeal carcinoma, including the role of HPV infection.

Authors:  Georgios Psychogios; Konstantinos Mantsopoulos; Abbas Agaimy; Kathrin Brunner; Elisabeth Mangold; Johannes Zenk; Heinrich Iro
Journal:  Biomed Res Int       Date:  2014-03-31       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.